Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.

Autor: Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA., Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Tolaney SM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Loirat D; Institut Curie, Paris, France., Punie K; Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Oliveira M; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Brufsky A; Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA., Kalinsky K; Winship Cancer Institute, Emory University, Atlanta, GA., Cortés J; International Breast Cancer Center, Quiron Group, Barcelona, Spain., Shaughnessy JO; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX., Diéras V; Centre Eugène Marquis, Rennes, France., Carey LA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Gianni L; Gianni Bonadonna Foundation, Milan, Italy., Piccart-Gebhart M; Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium., Loibl S; Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany., Yoon OK; Gilead Sciences, Inc, Foster City, CA., Pan Y; Gilead Sciences, Inc, Foster City, CA., Hofsess S; Gilead Sciences, Inc, Morris Plains, NJ., Phan SC; Gilead Sciences, Inc, Foster City, CA., Hurvitz SA; Division of Hematology and Oncology, Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 May 20; Vol. 42 (15), pp. 1738-1744. Date of Electronic Publication: 2024 Feb 29.

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.

Autor: Villacampa, Guillermo, Navarro, Victor, Matikas, Alexios, Ribeiro, Joana Mourato, Schettini, Francesco, Tolosa, Pablo, Martínez-Sáez, Olga, Sánchez-Bayona, Rodrigo, Ferrero-Cafiero, Juan M., Salvador, Fernando, Papakonstantinou, Andri, Prat, Aleix, Oliveira, Mafalda, Pascual, Tomas

Publikováno v: JAMA Oncology; Oct2024, Vol. 10 Issue 10, p1331-1341, 11p

Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors.

Autor: Udvorková, Natália, Fekiačová, Adriana, Majtánová, Kristína, Mego, Michal, Kučerová, Lucia

Publikováno v: American Journal of Physiology: Cell Physiology; Aug2024, Vol. 327 Issue 2, pC362-C371, 10p

Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer.

Autor: Seban RD; Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210, Saint-Cloud, France. romain.seban@gmail.com.; Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, PSL University, Institut Curie, Paris Saclay University, 91400, Orsay, France. romain.seban@gmail.com., Champion L; Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210, Saint-Cloud, France.; Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, PSL University, Institut Curie, Paris Saclay University, 91400, Orsay, France., De Moura A; Department of Medical Oncology, Institut Curie, 92210, Saint-Cloud, France., Lerebours F; Department of Medical Oncology, Institut Curie, 92210, Saint-Cloud, France., Loirat D; Department of Medical Oncology, Institut Curie, 75005, Paris, France., Pierga JY; Department of Medical Oncology, Institut Curie, Université Paris Cité, 75005, Paris, France.; Circulating Tumor Biomarkers Laboratory, INSERM CIC BT-1428, Institut Curie, Paris, France., Djerroudi L; Department of Pathology, Institut Curie, 75005, Paris, France., Genevee T; Department of Pharmacy, Institut Curie, 92210, Saint-Cloud, France., Huchet V; Department of Nuclear Medicine, Institut Curie, 75005, Paris, France., Jehanno N; Department of Nuclear Medicine, Institut Curie, 75005, Paris, France., Bidard FC; Department of Medical Oncology, Institut Curie, UVSQ/Paris-Saclay University, 92210, Saint-Cloud, France.; Circulating Tumor Biomarkers Laboratory, INSERM CIC BT-1428, Institut Curie, Paris, France., Buvat I; Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, PSL University, Institut Curie, Paris Saclay University, 91400, Orsay, France.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Oct 07. Date of Electronic Publication: 2024 Oct 07.

Technology-based supportive care for metastatic breast cancer patients.

Autor: Schmitz, Kathryn H., Kanski, Beth, Gordon, Brett, Caru, Maxime, Vasakar, Monali, Truica, Cristina I., Wang, Ming, Doerksen, Shawna, Lorenzo, Abby, Winkels, Renata, Qiu, Ling, Abdullah, Saeed

Publikováno v: Supportive Care in Cancer; Jul2023, Vol. 31 Issue 7, p1-9, 9p